Product Description
Mechanisms of Action: NMDA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merz
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Tinnitus|Alzheimer Disease
Phase 2: Chronic Pain|Cancer Pain|Tinnitus|Nystagmus, Congenital|Pain, Postoperative|Multiple Sclerosis|Nystagmus, Pathologic|Acute Pain
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2011-004998-83 | P2 |
Completed |
Unknown |
2013-07-09 |
|
| OLLTT | P3 |
Terminated |
Tinnitus |
2011-12-01 |
|
| 2008-001432-13 | P3 |
Terminated |
Tinnitus |
2011-10-12 |
|
| 2009-011246-25 | P3 |
Completed |
Tinnitus |
2011-06-03 |